Amira Pharmaceuticals Inc. BD opportunity scan covering pipeline ownership, stage, evidence package, IP risk, deal precedent, financial signals and outreach rationale using PatSnap MCP.

Vidutolimod: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.

Interferon gamma (Nostrum): Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.

Entinostat/Erlotinib Hydrochloride: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.

Ardea Biosciences, Inc BD opportunity scan covering pipeline ownership, stage, evidence package, IP risk, deal precedent, financial signals and outreach rationale using PatSnap MCP.

ZymoGenetics, Inc BD opportunity scan covering pipeline ownership, stage, evidence package, IP risk, deal precedent, financial signals and outreach rationale using PatSnap MCP.

Tanox, Inc BD opportunity scan covering pipeline ownership, stage, evidence package, IP risk, deal precedent, financial signals and outreach rationale using PatSnap MCP.

The Medicines Company BD opportunity scan covering pipeline ownership, stage, evidence package, IP risk, deal precedent, financial signals and outreach rationale using PatSnap MCP.

ViiV Healthcare BD opportunity scan covering pipeline ownership, stage, evidence package, IP risk, deal precedent, financial signals and outreach rationale using PatSnap MCP.

Synageva Biopharma Corp. BD opportunity scan covering pipeline ownership, stage, evidence package, IP risk, deal precedent, financial signals and outreach rationale using PatSnap MCP.

Tesaro, Inc. BD opportunity scan covering pipeline ownership, stage, evidence package, IP risk, deal precedent, financial signals and outreach rationale using PatSnap MCP.

VST Bio Corporation BD opportunity scan covering pipeline ownership, stage, evidence package, IP risk, deal precedent, financial signals and outreach rationale using PatSnap MCP.